EUVIMEDEUVIMED entdecken
Crossref

Dosimetric study of dose de-escalation using MRI-guidance for Pd-103 low-dose-rate brachytherapy in prostate cancer

Andrew Xue, Lin Wang, Meredith Akerman, Aarush Gogineni, Anthony Coelho, Louis Potters, Bhupesh Parashar

Brachytherapy · 2026

DOI: 10.1016/j.brachy.2025.12.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brachytherapy, 2026. Verfasst von Andrew Xue und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Medicine, Zucker School of Medicine, Northwell Health, Lake Success, New York, NY. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Palladium, Brachytherapy, Radioisotopes. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Despite the prevalence of prostate malignancies, there remains a need to improve toxicity profiles while maintaining oncologic control. Standard whole-gland treatment prescriptions have been associated with rectal, bladder, and urethral toxicity. This dosimetric study evaluated a differential dosing approach using Pd-103 low-dose-rate brachytherapy that delivers full prescription dose (125 Gy) to MRI-visible lesions while reducing dose to uninvolved prostate tissue (100 Gy). METHODS: Twenty-seven patients with unifocal, MRI-visible, biopsy-proven low- or intermediate-risk prostate cancer were identified. For each patient, two dosimetric plans were generated: a standard plan prescribing 125 Gy to the entire prostate, and a de-escalation plan prescribing 125 Gy to the MRI-visible lesion and 100 Gy to the remaining prostate. Dosimetric parameters including rectal D0.1cc and D2cc, bladder D2cc and D10cc, and urethral D10% and D30% were compared using Wilcoxon signed-rank tests. RESULTS: Fifty-four plans (27 standard, 27 de-escalation) were analyzed. The de-escalation approach achieved statistically significant dose reductions to all organs at risk (p 20%). While these dosimetric improvements suggest potential for reduced toxicity, clinical validation through our ongoing prospective Phase II trial is needed to confirm clinical benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsPalladiumBrachytherapyRadioisotopesMagnetic Resonance ImagingHumansMaleRadiotherapy DosageAgedRadiotherapy Planning, Computer-AssistedMiddle AgedRectumAged, 80 and over

Stichwörter der Autor:innen

BrachytherapyDosimetryMRIPd-103Prostate

Substanzen

PalladiumRadioisotopesPalladium-103

Autor:innen und Institutionen

  • Department of Radiation Medicine, Zucker School of Medicine, Northwell Health, Lake Success, New York, NY.
  • Biostatistics Unit, Office of Academic Affairs, Northwell Health, New Hyde Park, New York, NY.
  • Department of Radiation Medicine, Zucker School of Medicine, Northwell Health, Lake Success, New York, NY. Electronic address: bparashar@northwell.edu.

Zitieren

APA

Xue, A., Wang, L., Akerman, M., Gogineni, A., Coelho, A., Potters, L., & Parashar, B. (2026). Dosimetric study of dose de-escalation using MRI-guidance for Pd-103 low-dose-rate brachytherapy in prostate cancer. Brachytherapy. https://doi.org/10.1016/j.brachy.2025.12.010

Vancouver

Xue A, Wang L, Akerman M, Gogineni A, Coelho A, Potters L, et al. Dosimetric study of dose de-escalation using MRI-guidance for Pd-103 low-dose-rate brachytherapy in prostate cancer. Brachytherapy. 2026. doi:10.1016/j.brachy.2025.12.010

BibTeX
@article{Xue2026,
  author = {Xue, Andrew and Wang, Lin and Akerman, Meredith and Gogineni, Aarush and Coelho, Anthony and Potters, Louis and Parashar, Bhupesh},
  title = {Dosimetric study of dose de-escalation using MRI-guidance for Pd-103 low-dose-rate brachytherapy in prostate cancer},
  journal = {Brachytherapy},
  year = {2026},
  doi = {10.1016/j.brachy.2025.12.010}
}
Kostenlos starten →